



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

March 13, 2020

Eric D. Shaff  
Chief Executive Officer  
Seres Therapeutics, Inc.  
200 Sidney Street  
Cambridge, Massachusetts 02139

**Re: Seres Therapeutics, Inc.**  
**Registration Statement on Form S-3**  
**Filed March 9, 2020**  
**File No. 333-237033**

Dear Mr. Shaff:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tim Buchmiller at (202) 551-3635 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Peter N. Handrinos, Esq.